Amprologix selected to pitch at the World Innovation…10 October 2022
October 2022 CSO Mat Upton joined 19 other start-ups that were selected from 700 applicants for a place at the…
October 2022 CSO Mat Upton joined 19 other start-ups that were selected from 700 applicants for a place at the Qatar Foundation WISH meeting on 4-6th October 2022.
April 2022 Gordon Barker, Amprologix CEO was selected to present our innovative antibiotic development approach at the Start-ups Session (https://amr-conference.com/start-ups-amr-conference-pitching-session/). The session, sponsored by INCATE and partners, was watched by potential investors and funders and included SMEs developing novel therapies through to vaccines and diagnostics.
January 2022 Amprologix and RefLab ApS (Copenhagen, Denmark) have collaborated on a project using an ex vivo human skin microdialysis model (below) to test pseudo-allergic reactions in the skin, without using animal models.
November 2021 Amprologix have contracted two leading Commercial Research Organisations to conduct pre-clinical work on lead compound, epidermicin NI01. Amprologix have contracted two leading Commercial Research Organisations to conduct pre-clinical work on lead compound, epidermicin NI01. A formulation was developed for delivery of NI01 to the nasal cavity and this was shown to retain antimicrobial […]
We are delighted to be working with Adrian Gare and Alex Starling at FRP, who have a great track record in early stage financing and bring a wealth of life science sector experience to the team.
Having been based in the Marine Building at Plymouth University for the last 2-years, the company is now moving to the Derriford Research Facility to accommodate our expansion plans as we transition into the clinical phase of our antibiotic discovery programmes.
Amprologix CSO collaborates with Dr Max Ryadnov from the UK’s National Physical Laboratory, to publish new data on the novel mode of action of epidermicin NI01. Findings are reported in the August issue of iScience.